CN102656281A - 用于测定非小细胞肺癌预后的诊断方法 - Google Patents
用于测定非小细胞肺癌预后的诊断方法 Download PDFInfo
- Publication number
- CN102656281A CN102656281A CN2010800593539A CN201080059353A CN102656281A CN 102656281 A CN102656281 A CN 102656281A CN 2010800593539 A CN2010800593539 A CN 2010800593539A CN 201080059353 A CN201080059353 A CN 201080059353A CN 102656281 A CN102656281 A CN 102656281A
- Authority
- CN
- China
- Prior art keywords
- copy number
- patient
- cyclin
- sample
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title claims abstract description 57
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title claims abstract description 57
- 238000004393 prognosis Methods 0.000 title abstract description 19
- 238000002405 diagnostic procedure Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 109
- 230000003350 DNA copy number gain Effects 0.000 claims abstract description 35
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 31
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 31
- 201000005202 lung cancer Diseases 0.000 claims abstract description 30
- 238000007901 in situ hybridization Methods 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 239000002853 nucleic acid probe Substances 0.000 claims abstract description 8
- 239000000523 sample Substances 0.000 claims description 254
- 206010028980 Neoplasm Diseases 0.000 claims description 91
- 101000738568 Homo sapiens G1/S-specific cyclin-E1 Proteins 0.000 claims description 68
- 201000011510 cancer Diseases 0.000 claims description 59
- 210000004027 cell Anatomy 0.000 claims description 44
- 210000004072 lung Anatomy 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 29
- 230000004083 survival effect Effects 0.000 claims description 27
- 238000012360 testing method Methods 0.000 claims description 26
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 150000007523 nucleic acids Chemical class 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 238000003752 polymerase chain reaction Methods 0.000 claims description 16
- 102100037858 G1/S-specific cyclin-E1 Human genes 0.000 claims description 15
- 238000005406 washing Methods 0.000 claims description 15
- 230000008859 change Effects 0.000 claims description 13
- 238000002512 chemotherapy Methods 0.000 claims description 13
- 210000005259 peripheral blood Anatomy 0.000 claims description 13
- 239000011886 peripheral blood Substances 0.000 claims description 13
- 238000012545 processing Methods 0.000 claims description 11
- 238000002493 microarray Methods 0.000 claims description 10
- 230000005855 radiation Effects 0.000 claims description 10
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 10
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 9
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 9
- 206010048612 Hydrothorax Diseases 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 210000004907 gland Anatomy 0.000 claims description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 208000003849 large cell carcinoma Diseases 0.000 claims description 7
- 238000011275 oncology therapy Methods 0.000 claims description 7
- 238000012163 sequencing technique Methods 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 4
- 238000009104 chemotherapy regimen Methods 0.000 claims description 3
- 238000005215 recombination Methods 0.000 claims description 2
- 230000006798 recombination Effects 0.000 claims description 2
- 230000002759 chromosomal effect Effects 0.000 abstract description 11
- 238000002271 resection Methods 0.000 abstract description 3
- 230000002068 genetic effect Effects 0.000 abstract description 2
- 108050006400 Cyclin Proteins 0.000 abstract 1
- 102000016736 Cyclin Human genes 0.000 abstract 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 abstract 1
- 239000013610 patient sample Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 42
- 238000009396 hybridization Methods 0.000 description 30
- 210000000349 chromosome Anatomy 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 24
- 230000003321 amplification Effects 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- 238000003745 diagnosis Methods 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 102000003909 Cyclin E Human genes 0.000 description 9
- 108090000257 Cyclin E Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 210000000621 bronchi Anatomy 0.000 description 9
- 239000012472 biological sample Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 7
- -1 amino Deoxyribose cytidine Nucleotide Chemical class 0.000 description 7
- 230000002380 cytological effect Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 4
- 239000013611 chromosomal DNA Substances 0.000 description 4
- 238000003759 clinical diagnosis Methods 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 210000002415 kinetochore Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 210000004224 pleura Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- QEQDLKUMPUDNPG-UHFFFAOYSA-N 2-(7-amino-4-methyl-2-oxochromen-3-yl)acetic acid Chemical compound C1=C(N)C=CC2=C1OC(=O)C(CC(O)=O)=C2C QEQDLKUMPUDNPG-UHFFFAOYSA-N 0.000 description 2
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003322 aneuploid effect Effects 0.000 description 2
- 208000036878 aneuploidy Diseases 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000088 lip Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000001370 mediastinum Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- LKLWLDOUZJEHDY-UHFFFAOYSA-N 7-hydroxy-2-oxochromene-3-carboxylic acid Chemical compound C1=C(O)C=C2OC(=O)C(C(=O)O)=CC2=C1 LKLWLDOUZJEHDY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000025637 Autosomal monosomy Diseases 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 101150056334 Ccne1 gene Proteins 0.000 description 1
- 102000004381 Complement C2 Human genes 0.000 description 1
- 108090000955 Complement C2 Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 101000608228 Homo sapiens NLR family pyrin domain-containing protein 2B Proteins 0.000 description 1
- 101000730599 Homo sapiens Pleckstrin homology domain-containing family F member 1 Proteins 0.000 description 1
- 101000942217 Homo sapiens Protein C19orf12 Proteins 0.000 description 1
- 101000849714 Homo sapiens Ribonuclease P protein subunit p29 Proteins 0.000 description 1
- 101000734214 Homo sapiens Unconventional prefoldin RPB5 interactor 1 Proteins 0.000 description 1
- 101000723615 Homo sapiens Zinc finger protein 536 Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010026673 Malignant Pleural Effusion Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100039890 NLR family pyrin domain-containing protein 2B Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 102100030264 Pleckstrin Human genes 0.000 description 1
- 102100032592 Pleckstrin homology domain-containing family F member 1 Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100032608 Protein C19orf12 Human genes 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100033622 Unconventional prefoldin RPB5 interactor 1 Human genes 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100027858 Zinc finger protein 536 Human genes 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000013010 irrigating solution Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- GRHBQAYDJPGGLF-UHFFFAOYSA-N isothiocyanic acid Chemical compound N=C=S GRHBQAYDJPGGLF-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 108010068249 mitochondrial RNA-processing endoribonuclease Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003550 mucous cell Anatomy 0.000 description 1
- GWVCIJWBGGVDJJ-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyl-n-(3-methoxypyrazin-2-yl)acetamide Chemical compound COC1=NC=CN=C1N(C(C)=O)S(=O)(=O)C1=CC=C(N)C=C1 GWVCIJWBGGVDJJ-UHFFFAOYSA-N 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 108010026735 platelet protein P47 Proteins 0.000 description 1
- 201000010968 pleomorphic carcinoma Diseases 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
Description
Claims (48)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610160180.9A CN105586433A (zh) | 2009-10-26 | 2010-10-25 | 用于测定非小细胞肺癌预后的诊断方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25495509P | 2009-10-26 | 2009-10-26 | |
US61/254955 | 2009-10-26 | ||
PCT/US2010/053900 WO2011056490A1 (en) | 2009-10-26 | 2010-10-25 | Diagnostic methods for determining prognosis of non-small cell lung cancer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610160180.9A Division CN105586433A (zh) | 2009-10-26 | 2010-10-25 | 用于测定非小细胞肺癌预后的诊断方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102656281A true CN102656281A (zh) | 2012-09-05 |
CN102656281B CN102656281B (zh) | 2016-04-20 |
Family
ID=43431901
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610160180.9A Pending CN105586433A (zh) | 2009-10-26 | 2010-10-25 | 用于测定非小细胞肺癌预后的诊断方法 |
CN201080059353.9A Expired - Fee Related CN102656281B (zh) | 2009-10-26 | 2010-10-25 | 用于测定非小细胞肺癌预后的诊断方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610160180.9A Pending CN105586433A (zh) | 2009-10-26 | 2010-10-25 | 用于测定非小细胞肺癌预后的诊断方法 |
Country Status (14)
Country | Link |
---|---|
US (2) | US9297045B2 (zh) |
EP (2) | EP2494071A1 (zh) |
JP (3) | JP2013507988A (zh) |
KR (2) | KR101815184B1 (zh) |
CN (2) | CN105586433A (zh) |
AU (1) | AU2010315601A1 (zh) |
BR (1) | BR112012009885A2 (zh) |
CA (1) | CA2778004C (zh) |
IL (1) | IL219367A0 (zh) |
MX (1) | MX2012004907A (zh) |
RU (1) | RU2012121874A (zh) |
TW (1) | TW201120449A (zh) |
WO (1) | WO2011056490A1 (zh) |
ZA (1) | ZA201203011B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107709578A (zh) * | 2015-06-25 | 2018-02-16 | 拉梅什·瓦拉巴恩尼 | 使用靶向特异性dna探针在生物样品中进行染色体多重分析的方法和系统 |
CN109609636A (zh) * | 2018-12-29 | 2019-04-12 | 上海交通大学医学院附属瑞金医院 | 一种肺腺癌差异性表达circRNA的检测试剂盒及其应用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021222816A1 (en) * | 2020-05-01 | 2021-11-04 | Cedars-Sinai Medical Center | Isolation and functional analysis of epithelial progenitor cells from the human lung |
KR20220060198A (ko) * | 2020-11-04 | 2022-05-11 | 국립암센터 | 유전자 복제수 변이 정보를 이용하여 췌장암 환자의 생존 예후를 예측하는 방법 |
KR102565761B1 (ko) | 2022-12-08 | 2023-08-10 | 한화시스템(주) | 주반사경의 플렉셔 마운트 본딩장치 |
KR102610066B1 (ko) | 2023-08-22 | 2023-12-05 | 한화시스템(주) | 주반사경의 플렉셔 마운트 본딩장치 및 본딩 방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006128195A2 (en) * | 2005-05-27 | 2006-11-30 | Dana-Farber Cancer Institute | Methods of diagnosing and treating cancer by detection of chromosomal abnormalities |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5756696A (en) | 1986-01-16 | 1998-05-26 | Regents Of The University Of California | Compositions for chromosome-specific staining |
US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
AU622426B2 (en) | 1987-12-11 | 1992-04-09 | Abbott Laboratories | Assay using template-dependent nucleic acid probe reorganization |
KR950013953B1 (ko) | 1990-01-26 | 1995-11-18 | 애보트 래보라토리즈 | 리가제 연쇄 반응에 적용가능한 표적 핵산의 증폭 방법 |
US5491224A (en) | 1990-09-20 | 1996-02-13 | Bittner; Michael L. | Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture |
US6174681B1 (en) | 1999-03-05 | 2001-01-16 | Mayo Foundation For Medical Education And Research | Method and probe set for detecting cancer |
EP1362124B1 (en) | 2001-02-20 | 2011-07-06 | Vysis, Inc. | Methods and probes for the detection of cancer |
CN1252283C (zh) | 2001-04-30 | 2006-04-19 | 关新元 | 卵巢癌的检测方法和试剂盒 |
US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
GB2411229B (en) | 2003-07-22 | 2006-04-12 | Hitachi Int Electric Inc | Object tracking method and object tracing apparatus |
JP2005304497A (ja) * | 2004-03-25 | 2005-11-04 | Joji Inasawa | 特定の癌関連遺伝子を用いる癌の検出方法及び癌の抑制方法 |
EP2527460B1 (en) | 2004-05-27 | 2014-12-24 | The Regents of The University of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
EP2163624A1 (en) | 2004-09-24 | 2010-03-17 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers by tRNA-dihydrouridine synthase activity of URLC8 |
KR100759288B1 (ko) | 2005-11-14 | 2007-09-17 | 가톨릭대학교 산학협력단 | 비교유전자보합법을 이용한 폐암 및 폐암의 하부유형 진단방법 |
US20100292090A1 (en) * | 2006-08-25 | 2010-11-18 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
WO2008050356A1 (en) | 2006-10-27 | 2008-05-02 | Decode Genetics | Cancer susceptibility variants on chr8q24.21 |
BRPI0908173A2 (pt) | 2008-02-21 | 2016-12-06 | Basf Se | composição para cuidado pessoal, e, método para fabricar uma composição ou uma formulação antimicrobiana para cuidado pessoal |
US8951725B2 (en) | 2008-04-14 | 2015-02-10 | Abbott Laboratories | Diagnostic methods for determining prognosis of non-small cell lung cancer |
-
2010
- 2010-10-25 CN CN201610160180.9A patent/CN105586433A/zh active Pending
- 2010-10-25 EP EP10774088A patent/EP2494071A1/en not_active Withdrawn
- 2010-10-25 BR BR112012009885A patent/BR112012009885A2/pt not_active IP Right Cessation
- 2010-10-25 AU AU2010315601A patent/AU2010315601A1/en not_active Abandoned
- 2010-10-25 CA CA2778004A patent/CA2778004C/en not_active Expired - Fee Related
- 2010-10-25 TW TW099136363A patent/TW201120449A/zh unknown
- 2010-10-25 US US12/910,892 patent/US9297045B2/en not_active Expired - Fee Related
- 2010-10-25 JP JP2012536915A patent/JP2013507988A/ja active Pending
- 2010-10-25 CN CN201080059353.9A patent/CN102656281B/zh not_active Expired - Fee Related
- 2010-10-25 MX MX2012004907A patent/MX2012004907A/es not_active Application Discontinuation
- 2010-10-25 EP EP13187129.5A patent/EP2682482A1/en not_active Withdrawn
- 2010-10-25 WO PCT/US2010/053900 patent/WO2011056490A1/en active Application Filing
- 2010-10-25 KR KR1020127013387A patent/KR101815184B1/ko active IP Right Grant
- 2010-10-25 KR KR1020177037598A patent/KR20180014059A/ko not_active Application Discontinuation
- 2010-10-25 RU RU2012121874/10A patent/RU2012121874A/ru not_active Application Discontinuation
-
2012
- 2012-04-23 IL IL219367A patent/IL219367A0/en unknown
- 2012-04-24 ZA ZA2012/03011A patent/ZA201203011B/en unknown
-
2015
- 2015-12-17 JP JP2015245932A patent/JP6106257B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-09 US US15/019,689 patent/US20160160298A1/en not_active Abandoned
-
2017
- 2017-03-02 JP JP2017039029A patent/JP2017136071A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006128195A2 (en) * | 2005-05-27 | 2006-11-30 | Dana-Farber Cancer Institute | Methods of diagnosing and treating cancer by detection of chromosomal abnormalities |
Non-Patent Citations (4)
Title |
---|
AMBER YASMEEN ET.AL.: "E- and A-type cyclins as markers for cancer diagnosis and prognosis", 《EXPERT REVIEW OF MOLECULAR DIAGNOSTICS,FUTURE DRUGS》 * |
ETEMADMOGHADAM DARIUSH ET.AL.: "Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas", 《CLINICAL CANCER RESEARCH》 * |
KENTARO NAKAYAMA ET.AL.: "Amplicon profiles in ovarian serous carcinomas", 《INTERNATIONAL JOURNAL OF CANCER》 * |
TAKAYUKI MISHINA ET.AL.: ""Cyclin E Expression,a Potential Prognostic Marker for Non-Small Cell Lung Cancers"", 《CLINICAL CANCER RESEARCH》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107709578A (zh) * | 2015-06-25 | 2018-02-16 | 拉梅什·瓦拉巴恩尼 | 使用靶向特异性dna探针在生物样品中进行染色体多重分析的方法和系统 |
CN109609636A (zh) * | 2018-12-29 | 2019-04-12 | 上海交通大学医学院附属瑞金医院 | 一种肺腺癌差异性表达circRNA的检测试剂盒及其应用 |
CN109609636B (zh) * | 2018-12-29 | 2021-11-30 | 上海交通大学医学院附属瑞金医院 | 一种肺腺癌差异性表达circRNA的检测试剂盒及其应用 |
Also Published As
Publication number | Publication date |
---|---|
EP2682482A1 (en) | 2014-01-08 |
KR101815184B1 (ko) | 2018-02-05 |
EP2494071A1 (en) | 2012-09-05 |
CA2778004A1 (en) | 2011-05-12 |
MX2012004907A (es) | 2012-06-14 |
CN102656281B (zh) | 2016-04-20 |
CA2778004C (en) | 2018-03-13 |
KR20120101016A (ko) | 2012-09-12 |
ZA201203011B (en) | 2012-12-27 |
IL219367A0 (en) | 2012-06-28 |
KR20180014059A (ko) | 2018-02-07 |
AU2010315601A1 (en) | 2012-05-10 |
RU2012121874A (ru) | 2013-12-10 |
JP2017136071A (ja) | 2017-08-10 |
JP2013507988A (ja) | 2013-03-07 |
TW201120449A (en) | 2011-06-16 |
WO2011056490A1 (en) | 2011-05-12 |
JP2016105710A (ja) | 2016-06-16 |
US9297045B2 (en) | 2016-03-29 |
CN105586433A (zh) | 2016-05-18 |
BR112012009885A2 (pt) | 2016-11-29 |
US20110130295A1 (en) | 2011-06-02 |
JP6106257B2 (ja) | 2017-03-29 |
US20160160298A1 (en) | 2016-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104232762B (zh) | 用于测定非小细胞肺癌预后的诊断方法 | |
US20180291467A1 (en) | Diagnostic methods for determining prognosis of non-small cell lung cancer | |
JP6106257B2 (ja) | 非小細胞肺癌の予後を決定するための診断方法 | |
JP6542424B2 (ja) | 非小細胞肺癌の予後に関連する染色体異常の検出 | |
US8785131B2 (en) | Prognostic test for early stage non small cell lung cancer (NSCLC) | |
EP2132330A2 (en) | Methods and tools for detecting the presence of colorectal adenocarcinoma cells | |
WO2020036929A1 (en) | Arrays targeting differentially accessible chromatin regions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ABBOTT HOSPITAL CO., LTD. Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG Effective date: 20131210 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Bahamas Nassau Applicant after: AbbVie Inc. Address before: Bahamas Nassau Applicant before: Abbott Laboratories Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: ABBOTT HOSPITAL CO., LTD. TO: ABBVIE BAHAMAS B.V. |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20131210 Address after: Bahamas Nassau Applicant after: Abbott Laboratories Ltd. Address before: Illinois State Applicant before: ABBOTT LABORATORIES |
|
ASS | Succession or assignment of patent right |
Owner name: ABBOTT GMBH. + CO. KG Free format text: FORMER OWNER: ABBVIE BAHAMAS B.V. Effective date: 20150204 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150204 Address after: Illinois State Applicant after: ABBOTT LABORATORIES Address before: Bahamas Nassau Applicant before: AbbVie Inc. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160420 Address after: Illinois State Patentee after: ABBOTT MOLECULAR Inc. Address before: Illinois State Patentee before: ABBOTT LABORATORIES |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160420 Termination date: 20181025 |
|
CF01 | Termination of patent right due to non-payment of annual fee |